Melasma in Indian Skin — Why It Keeps Coming Back and What the Korean Protocol Actually Does Differently

Key Takeaways

• Melasma is not simply a pigmentation problem. It is a condition of hyperactive melanocytes — skin cells whose pigment production has been permanently upregulated by hormonal triggers — that is perpetuated by UV exposure every time the condition is cleared.
• The reason melasma keeps coming back is that most treatments address the pigmentation deposits without addressing the hormonal sensitisation and UV perpetuation that cause them to reform.
• Indian skin (Fitzpatrick III–V) is significantly more susceptible to treatment-induced worsening — post-inflammatory hyperpigmentation triggered by poorly calibrated peels or laser — than the skin types most pigmentation protocols were designed for.
• The Korean Pigmentation Correction Therapy introduced at Glam after CosmoBeauty Seoul 2026 addresses both the surface deposits and the inflammatory perpetuation cycle simultaneously — with anti-inflammatory formulation built into the treatment itself.
• No treatment for melasma produces permanent results without daily SPF50. UV is the perpetuating trigger. Without blocking it, every treatment is undone the first morning you step outside without sunscreen.
• Melasma in Indian skin is best understood as a managed condition — like blood pressure or blood sugar — that requires ongoing maintenance rather than a single corrective intervention.

Of all the skin concerns I see in Mumbai, melasma is the one that arrives with the most history. Clients who come to me with melasma have almost always been treated before — a cream from another dermatologist, a peel at a clinic, a laser session that produced initial clearing followed by return. The story is remarkably consistent: treatment produces results, the results last weeks to months, the melasma comes back — sometimes darker than before if the treatment was poorly calibrated. Another treatment. Another cycle.

The frustration in the room during these consultations is specific. It is not the frustration of someone who has given up. It is the frustration of someone who has kept trying — consistently, expensively, hopefully — and found that doing everything they were told was not enough. That frustration deserves a clinical explanation, not reassurance. This blog is that explanation.

What Melasma Actually Is — The Clinical Definition

Melasma is a chronic, acquired hyperpigmentation condition characterised by symmetrical, irregular patches of brown to grey-brown pigmentation, most commonly on the face — particularly the cheeks, upper lip, forehead, and chin. It is significantly more prevalent in women than men (approximately 90% of cases), predominantly affects people with darker skin phototypes (Fitzpatrick III–VI), and has two primary triggers: hormonal stimulation and UV radiation.

The mechanism at the cellular level is a permanent upregulation of melanocyte activity. In melasma, the melanocytes — the cells responsible for producing the pigment melanin — have been triggered into a state of chronic hyperactivity. They produce melanin at a rate that significantly exceeds what UV protection alone requires, and they respond to any stimulation — hormonal fluctuation, UV exposure, heat, inflammation — by producing even more. The visible patches on the skin are the accumulated excess melanin transferred to surrounding keratinocytes.

This is the foundational reason melasma is difficult to treat: you can clear the melanin deposits that are already visible. You cannot, with current treatments, reset the melanocyte to its pre-melasma state of activity. The hyperactivity persists. Every time the right trigger appears, the pigmentation reforms.

The Two Drivers of Melasma — And Why Both Must Be Managed

Driver 1: Hormonal Sensitisation

The most common hormonal trigger for melasma in Indian women is oestrogen — specifically the elevation in oestrogen associated with pregnancy (chloasma, or the “mask of pregnancy”), oral contraceptive use, and hormone replacement therapy. Oestrogen directly stimulates melanocyte-stimulating hormone (MSH) and activates oestrogen receptors on melanocytes themselves, upregulating their pigment production capacity. Once this upregulation has occurred, it does not simply reverse when the hormonal trigger is removed — the melanocytes remain in a sensitised state, ready to overproduce melanin in response to the next trigger.

Progesterone contributes to this sensitisation in a complementary way, and the combined oral contraceptive pill — which contains both — is the single most common pharmaceutical trigger for melasma in Mumbai’s young professional female population. This is a clinical conversation that many clients have not had, because it requires a dermatologist who takes a full hormonal history rather than treating the patches as a simple topical concern.

For clients on the combined pill whose melasma has not responded adequately to topical treatment, the conversation about contraceptive alternatives — progestogen-only methods, non-hormonal options — is part of the treatment plan. This is not a recommendation to stop hormonal contraception. It is an honest clinical acknowledgement that continuing the same hormonal trigger while treating its skin consequence is a cycle that cannot fully close.

Driver 2: UV Perpetuation

UV radiation is the most powerful perpetuating trigger for melasma in Indian skin — and Mumbai’s year-round UV environment makes this particularly significant. UV directly stimulates melanocyte pigment production through two mechanisms: it triggers the pituitary gland to release alpha-MSH, which activates melanocytes systemically; and it directly activates melanocyte surface receptors through the paracrine signals of surrounding keratinocytes damaged by UV.

In practice: every morning that a melasma patient steps outside without SPF50, they are applying the most powerful melanocyte stimulant available to their already-hyperactive melanocytes. The treatment that took eight weeks of clinical sessions to produce clears the visible pigmentation in the morning’s sun exposure. This is not hyperbole — it is the direct mechanism by which melasma undoes treatment in inadequately sun-protected skin.

Mumbai’s UV intensity is year-round and penetrates cloud cover at 70–80% intensity even in the monsoon season. SPF50 every morning — reapplied at midday for clients who are outdoors — is not optional in a melasma treatment programme. It is the treatment’s most important component. Without it, every clinical treatment is building on a foundation that is being eroded daily.

Why Standard Treatments Often Make Melasma Worse — Particularly in Indian Skin

This is the conversation most clients with a history of treatment-worsened melasma have been waiting to have. When a peel or laser makes melasma worse — and this happens with significant frequency in Indian skin treated with protocols not calibrated for darker Fitzpatrick types — the mechanism is the same PIH risk I described in the Blog 9 of this series.

Melasma-affected melanocytes are already in a state of hyperactivity. When a treatment creates inflammation — as any peel, any laser, and any aggressive active creates by design — the inflamed skin triggers a melanocyte protective response. In darker skin with hyperactive melanocytes, this protective response produces melanin at an accelerated rate. The treatment that was intended to clear pigmentation instead stimulates additional pigmentation production. The patches darken. The client leaves worse than they arrived.

This is not a rare complication in Indian skin treated with standard melasma protocols. It is the expected outcome when the inflammatory threshold of the treatment exceeds the skin’s tolerance — which, for Fitzpatrick IV and V skin with hyperactive melanocytes, is a lower threshold than the protocols designed for Fitzpatrick II and III skin account for.

The solution is not to avoid treating melasma. It is to treat it with protocols that have been designed for the specific inflammatory sensitivity of melanin-rich skin — which is precisely what Korean aesthetic medicine, in its approach to pigmentation correction, does better than Western protocols.

What the Korean Pigmentation Correction Therapy Does Differently

I introduced the Korean Pigmentation Correction Therapy at Glam following CosmoBeauty Seoul 2026 specifically because it addresses the gap I have described above. Here is what makes it structurally different from standard melasma treatment approaches:

Anti-Inflammation Built Into the Treatment, Not Managed Afterwards

The Korean formulation combines the pigmentation-correcting actives with anti-inflammatory components that suppress the melanocyte response during the treatment itself. This is not aftercare. It is formulation design — the recognition that any treatment on hyperactive melanocytes in dark skin must simultaneously produce correction and suppress the inflammatory cascade that would trigger further pigmentation. This structural approach reduces PIH risk from the treatment itself in a way that no aftercare protocol can reliably replicate.

Multi-Layer Targeting

Melasma deposits exist at multiple depths in the epidermis — and sometimes extend into the dermis in epidermal-dermal and dermal subtypes. A treatment that addresses only surface deposits clears the visible top layer while deeper deposits remain, producing improvement that reverses quickly as the deeper pigmentation migrates to the surface. The Korean Pigmentation Correction Therapy uses a sequenced protocol that addresses surface, mid-epidermal, and where appropriate, deeper deposits — producing more complete clearing and a longer maintenance interval between sessions.

Calibrated for South Asian Skin, Not Extrapolated From Lighter Skin Trials

The clinical validation behind this Korean formulation includes specific data on South Asian skin types — not extrapolations from studies on Fitzpatrick I–III skin applied to darker patients. This matters because the concentration of every active ingredient, the pH of the formulation, and the timing of the treatment protocol all need to be set for the melanocyte sensitivity of the skin being treated. A formulation calibrated on Fitzpatrick II skin applied to Fitzpatrick V skin is a different clinical event — with different outcomes and different risk profiles.

“Melasma is one of the most challenging pigmentary disorders to treat, particularly in patients with skin of colour, where treatment-associated post-inflammatory hyperpigmentation is a significant risk that must be managed through protocol design, not simply through aftercare instructions.”

The Complete Melasma Management Programme at Glam

Melasma requires a layered, multi-component approach. Here is the programme structure I use at Glam for clients presenting with established melasma:

Foundation — Non-Negotiable From Day One

• SPF50 PA++++ every morning — applied generously to all sun-exposed areas, reapplied at midday for outdoor exposure. This is the most important part of the entire programme. Everything else depends on this being done consistently.
• Hormonal history review — to identify whether hormonal contraception, pregnancy, or HRT is an active driver, and to discuss management options where relevant.

Topical Programme — Between Sessions

• Tranexamic acid — inhibits the UV-triggered release of arachidonic acid that stimulates melanocyte activity; one of the most evidence-backed topical treatments for melasma specifically
• Azelaic acid — gentle tyrosinase inhibitor with anti-inflammatory properties; safe for Fitzpatrick IV–V and appropriate for use in pregnancy
• Niacinamide — inhibits melanin transfer from melanocytes to keratinocytes, reducing the visible pigmentation at the surface level

Clinical Programme — Monthly Sessions

• Korean Pigmentation Correction Therapy — the primary corrective treatment, addressing existing deposits at multiple depths without triggering PIH
• Pico laser — for dermal melasma or surface deposits that do not respond adequately to the peel protocol; carefully calibrated for Fitzpatrick type and spaced appropriately within the treatment programme
• PDRN booster — addressing the chronic inflammation that perpetuates melanocyte hyperactivity, supporting the anti-inflammatory dimension of the programme at the cellular level

Maintenance — After Clearance

Once visible melasma has cleared, the maintenance programme continues. Not because the melasma will inevitably return — but because without ongoing UV protection and periodic clinical maintenance, it will. Clients who maintain SPF50 rigorously and return for a Korean Pigmentation Correction session every three to four months consistently sustain their clear skin. Clients who treat, clear, and then return to unprotected sun exposure are in a cycle that requires new treatment every season.

The Questions Melasma Patients Ask Most Often

I have been using a hydroquinone cream for two years. Why hasn’t it worked?

Hydroquinone is a topical tyrosinase inhibitor — it blocks one step in the melanin production pathway. At appropriate concentrations and with consistent use, it produces visible lightening of surface pigmentation. However, it does not address the dermal component of melasma, it does not suppress the UV-triggered reactivation of melanocytes, and it does not work if the hormonal driver is still active. Two years without meaningful improvement suggests that the limitation is not the product but the unaddressed drivers — hormonal or UV perpetuation — that are maintaining the melanocyte activity that the hydroquinone is trying to suppress. A clinical consultation to reassess the programme is the appropriate next step.

My melasma got darker after a peel at another clinic. Can I still get treated?

Yes — but the treatment programme must specifically account for your previous PIH experience. Your skin’s melanocyte response to inflammation has been demonstrated to be significant, which means the Korean Pigmentation Correction Therapy’s anti-inflammatory formulation design is particularly important for you specifically. Pre-treatment preparation — topical melanocyte stabilisation for four to six weeks before any corrective treatment — is also essential in your case. Many of my most satisfying clinical outcomes at Glam involve clients whose previous poorly-calibrated treatment has been successfully addressed and whose melasma is now genuinely clearing without recurrence.

I am pregnant. Can I get melasma treatment?

During pregnancy, treatment options are limited by safety considerations. Topical azelaic acid and niacinamide are generally considered safe in pregnancy. Most peels, laser treatments, and stronger actives are avoided during this period. The most important intervention during pregnancy is rigorous SPF50 every morning to prevent UV from further perpetuating the melasma. Post-delivery — and once breastfeeding has concluded if relevant — the full treatment programme can begin. Many clients find that melasma partially improves naturally after hormonal levels normalise post-pregnancy; what remains at three to six months post-delivery responds well to the clinical programme.

My husband also has melasma. Is it the same condition in men?

Yes — melasma in men presents identically in terms of distribution and appearance, but the hormonal driver is different: male melasma is almost entirely UV-driven rather than hormonally driven. This means the maintenance programme for male melasma is primarily about rigorous UV protection, with fewer concerns about hormonal triggers. Male melasma also responds well to the Korean Pigmentation Correction Therapy — the treatment is not gender-specific — though the absence of hormonal drivers means the recurrence risk with adequate sun protection is lower than in female melasma cases.

Melasma Has a Treatment Programme That Works — When It Addresses Both Drivers

The clients who clear their melasma and keep it clear are the clients who understand that they are managing a condition, not correcting a cosmetic concern. The Korean Pigmentation Correction Therapy addresses the visible pigmentation deposits with a formulation designed for Indian skin. The SPF protects the progress from daily UV erosion. The hormonal management closes the driver that restarts the cycle. Together, they produce outcomes that the standard cycle of treat-clear-return does not.

At Glam Korean Skin Studio in Andheri West, Dr Akansha’s melasma programme is built on this three-component foundation — with the Korean Pigmentation Correction Therapy, sourced directly from CosmoBeauty Seoul 2026, as its clinical centrepiece. If you have been treating your melasma for years without sustained results, the consultation is where the cycle begins to change.

Book a Melasma Consultation at Glam Korean Skin Studio, Andheri West →
Aston Building, 802, Lokhandwala Rd, above Mercedes showroom, Sundervan Complex, Shastri Nagar, Andheri West, Mumbai 400053
+91 93269 69657 · Get Directions